[Effects of verapamil on the proliferation and migration of cervical cancer cells].

OBJECTIVE: To investigate the effects of Verapamil, a L-type calcium channel blocker, on the proliferation and migration of human cervical cancer cells. METHODS: Human cervical cancer cell lines (HeLa cells) were incubated with serum-free media for 24 hours. These cells were then treated with Verapamil for different time points. Cell proliferation was evaluated by MTT assay and EdU fluorescent assay. The migration of cells was measured by the wound healing assay. Results MTT assay demonstrated that, Verapamil (1, 5, 10 and 20 microg/mL concentrations) could inhibit the proliferation of HeLa cells after 48 or 72 hours treatment. The inhibition rate for 48 h-treatment was 20.87% +/- 1.71%, 23.55% +/- 4.46%, 28.65% +/- 1.32%, 27.37% +/- 3.05% respectively (P < 0.05). After 5, 10 and 20 microg/mL concentrations of verapamil treatment for 24h, the proportion of HeLa cells in the stage of DNA synthesis was 15.7% +/- 1.2%, 11.7% +/- 0.3%, 2.8% +/- 0.5% as evaluated with EdU fluorescent assay, which was significantly lower than that of control (27.34% +/- 2.1%, P < 0.05). With the increase of drug concentrations, Verapamil could significantly suppressed the DNA synthesis in HeLa cell. Cell migration assay revealed that, treatment with Verapamil (5, 10 and 20 microg/mL) for 24 hours significantly inhibited cells migration distance (P < 0.05). CONCLUSION: Calcium channel blocker Verapamil could inhibit proliferation and migration of the cervical cancer HeLa cells.

Systematic comparison of radical vaginal trachelectomy and radical hysterectomy in the treatment of early-stage cervical cancer.

OBJECTIVE: To review the effects of radical vaginal trachelectomy (RVT) and radical hysterectomy (RH) on overall progression-free survival rate, and intraoperative and postoperative complications in patients with cervical cancer (FIGO stage IA-IB1). METHODS: Electronic searches for studies of RVT and RH in the treatment of cervical cancer between 1994 and January 2010 were made on MEDLINE, the Cochrane Library, the China National Knowledge Infrastructure, and the Wan Fang dissertation database. RESULTS: No significant differences were found between RVT and RH in 5-year overall survival rate (relative risk [RR] 0.97; 95% confidence interval [CI], 0.93-1.02); 5-year progression-free survival rate (RR 0.99; 95% CI, 0.95-1.02); intraoperative complications (RR 1.99; 95% CI, 0.61-6.52)]; and postoperative complications (RR 0.36; 95% CI, 0.10-1.27). There were fewer blood transfusions (RR 0.33; 95% CI, 0.12-0.90), less blood loss, and shorter hospital stays in patients undergoing RVT. CONCLUSION: Radical vaginal trachelectomy should be considered as a viable treatment option for young patients with early cervical cancer (FIGO stage IA-IB1) who wish to preserve their fertility.

[Relationship between polymorphism of hypoxia inducible factor-1alpha and cervical cancer in Han population in Sichuan Province of China].

OBJECTIVE: To investigate the relationship between single nucleotide polymorphism (SNP) of hypoxia inducible factor-1alpha (HIF-1alpha) C1772T and genetic susceptibility to and clinical-pathological features of cervical cancers in Han population in Sichuan province of China. METHODS: A case control study was undertaken in Sichuan province of China, with 97 patients with uterine cervical cancer as case group and 117 negative for intraepithelial lesion or malignancy (NILM) patients as control group. Their gene types in HIF-1alpha C1772T were identified with a combination of polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). RESULTS: The distribution of the frequencies of T/T, T/C and C/C genotypes in the two groups differed significantly (P < 0.01); T allele frequency in the patients with cervical cancer was much higher than that in the controls (P < 0.01). There were no significant differences in the distributions of T/T, T/C and C/C genotypes among cervical cancer patients at different FIGO stages, pathological grading, stromal invasive depth, lymph node metastasis and vascular invasions (P > 0.05). CONCLUSION: T/C and T/T genotypes of HIF-1alpha C1772T are genetic susceptibility factors for cervical cancer in Han population in Sichuan province of China. HIF-1alpha C1772T SNP probably has no relationship with clinical-pathological features of cervical cancer.

[Influences of human beta-defensin 1 on the replication and expression of HPV18 in Hela cell].

OBJECTIVE: Investigate the influences of human beta-defensinl (hbetaD1) on the replication and expression of HPV18 in Hela cell. METHODS: Gene transfection: mediated by Fugen HD, hbetaD1/psectag plasmid was transfected to Hela cell [hbetaD1/psectag : liposome complexes (hbetaD1/psectag : lip)group], and control groups [psectag : liposome complexes(psectag : lip) group and blank group) were also established. After transfection, the expression of the target gene in Hela cell was investigated by the method of immunocytochemistry. 48 h and 72 h after the transfection, the change of the copy number of HPV18 DNA in Hela cell was investigated respectively by the quantitative fluorescent PCR method, and the change of the HPV18 E6 mRNA in Hela cell was evaluated by the semiquantitative RT-PCR. RESULTS: 48 h and 72 h after the transfection of hbetaD1/psectag plasmid to Hela cell, hbetaD1 was expressed in both of the two groups, and the latter showed a tendency of stronger expression. Compared with the control groups, the copy number of HPV18 DNA in Hela cell in the hbetaD1/psectag : lip group increased at 48 h and decreased at 72 h after the transfection, but the change was not statistically significant. 48 h after the transfection, compared with the control groups, the expression of HPV18 E6 mRNA in Hela cell in the hbetaD1/psectag : lip group changed a little; and 72 h after the transfection, the expression level of HPV18 E6 mRNA decreased significantly (P < 0.05). CONCLUSION: hbetaD1 displayed an inhibitory effect to the expression of HPV18 mRNA in Hela cell in a concentration-dependent pattern, but no significant effect on the duplication of HPV18 DNA.

[An exploration of the expression of MK and MVD in cervical cancer tissues before and after NACT].

OBJECTIVE: To investigate the clinical effect of neoadjuvant chemotherapy (NACT) and its influence on the expressions of MK and MVD in cervical cancer cells. METHODS: The expressions of MK, CD34 were determined by immunohistochemistry in 35 cases of cervical cancer before and after NACT. RESULTS: Among the 35 cases treated with NACT, 4 (11.43%) were complete remission (CR), 25 (71.43%) partial remission (PR). The total effective rate of NACT (CR+PR) was 82.86%. The expressions of MK and MVD decreased dramatically after NACT. In cases who reacted positively to NACT, the expression of MK and the level of MVD decreased significantly after the treatment (P<0.05). While in cases who reacted poorly to NACT no such changes were observed in the expression of MK (P>0.05); but the level of MVD also decreased in those cases. CONCLUSION: NACT is an effective treatment for cervical cancer. The expressions of MK and MVD decreased after NACT treatment. It implied that one of the mechanisms of NACT may be the suppression of angiogenesis, and the expression of MK may serve as an indicator for predicting the therapeutic effect of NACT.

[Relationship between the expression of fragile histidine (FHIT) and the development of vulvar carcinoma].

OBJECTIVE: To explore the relationship between the reduction of FHIT expression of fragile histidine (FHIT) and the development of vulvar carcinoma. METHODS: The expression of the FHIT product was detected by immunochemistry in the tissue samples of 20 normal vulvas, 22 vulvar intraepithelial neoplasias (VINs), and 60 primary vulvar carcinomas. RESULTS: The expressive rates of FHIT protein in the squamous epithelium of normal vulvas, VIN I - II, VIN II, and noninvasive and invasive vulvar carcinoma were 100% (20/20), 72.7% (8/11), 45.5% (5/11), and 21.7% (13/60) respectively (P<0.05). The expressive rates of FHIT protein in the well differentiated, intermediately differentiated and poorly differentiated invasive vulav carcinoma were 60.0% (9/15), 20.0% (3/15), and 3.3% (1/30) respectively (P<0.05). The expressive rate of the impaired FHIT protein in the invasive vulva carcinoma with lymphnode metastasis (10%) was lower than that without lymphnode metastasis (27.5%). CONCLUSION: Abnormal FHIT expression may play an important role in the progression of vulvar carcinoma. The expression of FHIT may provide important information for the prognosis of vulva carcinoma.